Company profile
ImmunoServ - Your Immunology Research Partner
ImmunoServ is uniquely positioned to perform both pre-clinical and clinical contract research in the immunology and cancer immunotherapy fields.
Financial period: 1 Nov 2023 to 31 Oct 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
CS01 | Transaction MzUyNTg0NDgwMGFkaXF6a2N4
Published 08 Jun 2026 07:22
Last accounts made up date
Last confirmation statement made up date
Company registered at Companies House
1 May 2025 to 30 Apr 2028
Group A Streptococcus (Strep A) is a major global health concern, causing over 600 million new infections each year. This bacterium can lead to a wide range of illnesses, from common conditions like sore throat and impetigo to more serious diseases like necrotising fasciitis and toxic shock syndrome. Repeated infections with Strep A can also result in lon...
1 Sep 2021 to 31 Aug 2022
As the current COVID-19 pandemic unfolds, we urgently require screening tools that determine who is sufficiently protected from the SARS-CoV-2 virus, which causes the disease. To enable the population and the economy to return to normal, it is important to know who has become immune to the virus through infection or vaccination. This includes individuals ...
